131 related articles for article (PubMed ID: 31886567)
1. Prognostic implication and functional annotations of Rad50 expression in patients with prostate cancer.
Xu WH; Wang J; Sheng HY; Qu YY; Wang HK; Zhu Y; Shi GH; Zhang HL; Ye DW
J Cell Biochem; 2020 Jun; 121(5-6):3124-3134. PubMed ID: 31886567
[TBL] [Abstract][Full Text] [Related]
2. Elevated MRE11 expression associated with progression and poor outcome in prostate cancer.
Wang J; Xu WH; Wei Y; Zhu Y; Qin XJ; Zhang HL; Ye DW
J Cancer; 2019; 10(18):4333-4340. PubMed ID: 31413753
[No Abstract] [Full Text] [Related]
3. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
[TBL] [Abstract][Full Text] [Related]
5. Elevated double-strand break repair protein RAD50 predicts poor prognosis in hepatitis B virus-related hepatocellular carcinoma: A study based on Chinese high-risk cohorts.
Liu W; Xu W; Chen Y; Gu L; Sun X; Qu Y; Zhang H; Liu X; Huang H
J Cancer; 2020; 11(20):5941-5952. PubMed ID: 32922536
[No Abstract] [Full Text] [Related]
6. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
7. ITGA2B and ITGA8 are predictive of prognosis in clear cell renal cell carcinoma patients.
Lu X; Wan F; Zhang H; Shi G; Ye D
Tumour Biol; 2016 Jan; 37(1):253-62. PubMed ID: 26198048
[TBL] [Abstract][Full Text] [Related]
8. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer.
Zhang H; Qi C; Wang A; Yao B; Li L; Wang Y; Xu Y
J Exp Clin Cancer Res; 2013 Oct; 32(1):77. PubMed ID: 24422979
[TBL] [Abstract][Full Text] [Related]
9. Homologous recombination mRNAs (RAD21, RAD50 and BARD1) have a potentially poor prognostic role in ERBB2-low bladder cancer patients.
Albarakati N; Al-Ghamdi H; Al-Sowayan B; Alshareeda A
Sci Rep; 2023 Jul; 13(1):11738. PubMed ID: 37474724
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
12. Decreased SPTLC1 expression predicts worse outcomes in ccRCC patients.
Zhu WK; Xu WH; Wang J; Huang YQ; Abudurexiti M; Qu YY; Zhu YP; Zhang HL; Ye DW
J Cell Biochem; 2020 Feb; 121(2):1552-1562. PubMed ID: 31512789
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis.
Ho V; Chung L; Singh A; Lea V; Abubakar A; Lim SH; Ng W; Lee M; de Souza P; Shin JS; Lee CS
BMC Cancer; 2018 Sep; 18(1):869. PubMed ID: 30176843
[TBL] [Abstract][Full Text] [Related]
15. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
[TBL] [Abstract][Full Text] [Related]
16. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
18. A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer.
Wang Y; Fan J; Chen T; Xu L; Liu P; Xiao L; Wu T; Zhou Q; Zheng Q; Liu C; Chan FL; Wu D
Front Endocrinol (Lausanne); 2022; 13():975623. PubMed ID: 36034466
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
Guo J; Wang M; Wang Z; Liu X
PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of COL6A1 is predictive of poor prognosis in clear cell renal cell carcinoma patients.
Wan F; Wang H; Shen Y; Zhang H; Shi G; Zhu Y; Dai B; Ye D
Oncotarget; 2015 Sep; 6(29):27378-87. PubMed ID: 26317545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
